Prof. Wojciech Jurczak

Enkele recente publicaties:

1. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group.N Engl J Med. 2017Dec 10. doi: 10.1056/NEJMoa1708984. [Epub ahead of print]
2. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.Lancet. 2017Dec 11. pii: S0140-6736(17)33108-2. doi: 10.1016/S0140-6736(17)33108-2. [Epub ahead of print]
3. Research on Biosimilars: pivotal trials and principles.Jurczak W, Vulto AG, Amersdorffer J, Kim WS, Coiffier B.Lancet Haematol. 2017Sep;4(9): e409-e410. doi: 10.1016/S2352-3026(17)30152-7.
4. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, Castro N, Pereira J, Akria L, Alexeev S, Osmanov E, Zhu P, Alexandrova S, Zubel A, Harlin O, Amersdorffer J.Lancet Haematol. 2017Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.